| ALK

Henning Løwenstein Research Award

Young scientists

The Henning Løwenstein Research Award

Henning Løwenstein

Henning Løwenstein contributed significantly to the identification, categorisation, isolation, characterisation, and nomenclature of allergens and allergen components, recombinant allergens, standardization of allergen extracts for diagnosis and treatment of allergic diseases as well as translation of research understandings into robust clinical trials.

To recognise this outstanding contribution, ALK established and dedicated The Henning Løwenstein Research Award to the researcher Henning Løwenstein on his 25th anniversary of working at the company.

allergy-on-rise
Allergy is on the rise affecting people’s lives

Over the last few decades, allergy has
increased in prevalence to become the most common chronic disease in modern societies. The causes for this change remain unclear although they seem to be linked to “modern lifestyle”. If left untreated, allergic rhinoconjunctivitis can progress with the development of new sensitisations and co-morbidities e.g., asthma. Furthermore, respiratory allergy has a significant impact on people’s lives and quality of life.

Recent research indicates that there is no simple dose-relationship between allergen exposure and symptoms. Symptom-relieving medication alleviates symptoms but does not prevent increases in the prevalence of allergy or the course of it. Allergy immunotherapy is the only treatment that targets the cause, induces immunological tolerance, and prompts disease modification meaning long-term and preventive effect.

ALK awards young scientists for excellence

In ALK, we believe that reinforced efforts in research on the characteristics and treatment of respiratory allergic disease will lead the way for future achievements to the benefit of people – children, adolescents, and adults – living with allergies all over the world. The Henning Løwenstein Research Award is a biannual award given to a young scientist who has shown excellence within the field of allergy. The winner receives a monetary grant* (€20,000 in 2024) and a travel grant to attend the award ceremony at ALK in Hørsholm, Denmark.

2024 Henning Løwenstein Research Award - won by Kelly Bruton

Application guidelines

Call for applications for the Henning Løwenstein Research Award 2025.

The next Henning Løwenstein Research Award ceremony will be held at ALK in Hørsholm, Denmark, in connection with SOSA 2025 in the fall.

Please see the application criterion below and submit your online application here.

Deadline for submission is 15 August 2025.

Application criterion (in 2025)
  • Applicants must be concise, max. 2 pages including essential references, and should describe previous and current research activities 
  • The applicant’s precise role in these activities must be clearly stated 
  • The applicant’s curriculum vitae must also be enclosed, max. 2 pages 
  • Applicants should be early in their academic career, within 10 years of their PhD (or equivalent degree), and should not be considered an established scientist, i.e., head of department, professor, etc.
Evaluation

An international Scientific Board will evaluate the applications. The members in 2025 are: 

  • Stephen Durham, Chairman of the award, England
  • Henning Løwenstein, Honorary of the award, Denmark
  • Stephen Till, England
  • Mark Larche, Canada
  • Motohiro Ebisawa, Japan
  • Natalija Novak, Germany
  • Jing Li, China

Previous award ceremonies and winners

​​2024 Henning Løwenstein Research Award - won by Kelly Bruton
2021 Henning Løwenstein Research Award - won by Julia Esser-von Bieren
2019 Henning Løwenstein Research Award – won by Kornel Golebski
The Henning Løwenstein Research Award

2024: Kelly Bruton, Stanford University, United States of America 

2021: Julia Esser-von Bieren, Technical University, Munich, Germany

The ARIA-EUFOREA Henning Løwenstein Research Award

2019: Kornel Golebski, University of Amsterdam, the Netherlands

The WAO Henning Løwenstein Research Award

2015: Stefanie Eyerich, Technical University and Helmholtz Center, Munich, Germany 

2013: Bianca Schaub, Ludwig-Maximilian-University, Munich, Germany 

2011: Zoulfia Allakhverdi, University of Montreal, Canada, and Natalija Novak, University of Bonn, Germany 

2009: Stephen J Till, Imperial College, London, United Kingdom 

2007: Barbara Bohle, Medical University of Vienna, Austria

The Henning Løwenstein Research Award

2005: Omid Akbari, Harvard University, United States of America 

2004: Christopher Lynn Kepley, Commonwealth University of Virginia, United States of America 

2003: Erika Ganglberger, University of Vienna, Austria 

2002: Miriam Fleur Moffatt, University of Oxford, United Kingdom 

2001: Eckard Hamelmann, Humboldt-University of Berlin, Germany 

2000: Mark Larché, Imperial College, London, United Kingdom

* If the winner is from a country where local legislation or medicolegal regulation prevents the transfer of monetary awards from the pharmaceutical industry to healthcare professionals, and in the case that the selected winner is a healthcare professional, the award is substituted by a travel grant or an educational grant of corresponding value. The grant is managed by ALK A/S and specified payment can only be given in the form of tickets or refund of tickets for a scientific or educational purpose, which is in agreement with the medicolegal regulation in that country. Accepted purposes could be transportation to a scientific congress or educational event, registration fees, educational charges or accommodation. ALK will ensure that each purpose is in agreement with the regulation in that particular country.

Last updated: 24.03.2025

Front Page (new)

ALK

Pioneering in the field of respiratory allergies for more than a century, we've embarked on a mission to help more people, with more solutions, more efficiently.

News

  • Post date
    05/08/2025
    ITULATEK® approved for treatment of children and adolescents in Canada
  • Post date
    05/06/2025
    Three-month interim report (Q1) 2025 (unaudited)
  • Post date
    05/02/2025
    ALK enters into neffy® co-promotion agreement in the USA
  • Post date
    04/29/2025
    Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
  • Post date
    04/23/2025
    ITULAZAX® tree pollen tablet approved for treatment of children in Europe
  • Post date
    04/03/2025
    Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
  • Post date
    03/13/2025
    Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
  • Post date
    03/07/2025
    ACARIZAX® approved in Canada for treatment of young children
  • Post date
    03/04/2025
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Apply for the Henning Løwenstein Research Award 2025
The prestigious Henning Løwenstein Research Award is given to a young scientist who has shown excellence within the field of allergy. Don't miss the opportunity to apply. The deadline is 15 August 2025.
ALK corporate strategy 2024-2028
As the pioneers of allergy solutions, we are stepping into the next 100 years with a mission to help more people, with more solutions, more efficiently. We call it Allergy+.
100 years of pioneering allergy solutions
A new book has been written about ALK’s fascinating development in the field of allergy
The hunt for a vaccine – a podcast in five episodes
A fascinating story about ALK and the company’s 100 years of hunting allergy vaccines have been turned into a captivating podcast.
Image
ALK homepage video thumbnail
We are the pioneers of allergy solutions

For more than a 100 years, ALK has been at the forefront of allergy research and treatment. We're on a mission to help even more people globally, reaching 5 million people a year by 2030.

ALK in brief

Avatar

Allergy solutions

Allergy is caused by an overreaction of the body’s immune system to substances that in most cases would otherwise be harmless. Learn about the chronic disease, diagnosis, and treatment options.

Avatar

Sustainability

We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.

Avatar

Careers

Become part of a team that is passionate about making a difference for people living with allergy. In our global company, we share expertise and knowledge across boarders and cultures and have a focus on continuous employee development.

Last updated: 02.06.2025

Strategy

ALK strategy 2028

Allergy+ — our approach to helping more people with allergy

We are the pioneers of allergy solutions

Allergy is the most common chronic disease globally and it has profound impact on people’s lives. More than 500 million people worldwide live with respiratory allergies, more than 200 million people have some sort of food allergy, and more than 100 million children are living with allergic rhinitis. These numbers are only expected to increase, and as a result, the need for allergy solutions is ever-growing.

For more than a 100 years, ALK has been at the forefront of long-term allergy treatment. Building on our strong heritage, our team is stepping into the next 100 years with a mission to help even more people, with more solutions, more efficiently. We call it Allergy+.

Allergy+ — ALK’s corporate strategy towards 2028

With this direction for the future, we are aiming for more. More specifically, we are aspiring to help 5 million people living with allergy annually by 2030 – that is more than double the number we helped in 2023.

Allergy+ is shaped by our mission to help people living with allergy, and they are therefore at the very centre of our four strategic pillars: Focus, Innovate, Optimise and Cultivate. Our strategy aims to further strengthen ALK’s leadership in long-term allergy treatment, establishing a leading position in food allergy and anaphylaxis, as well as pursuing new innovations to address adjacent allergic conditions with high unmet needs. It builds on our promise of providing life-changing solutions to the millions of people with allergy.

Image description

CEO Peter Halling says: “We want to sustain ALK’s growth for many years to come and leverage our insights and business platforms to help more people with allergies to a better life. The new strategy prioritises high-potential growth levers – markets, projects and innovations - with the largest potential to generate strong returns and the greatest impact for patients and prescribers. We will allocate resources carefully, and we will simplify and reduce complexity across our business to effectively scale up ALK for future growth in revenue and earnings.

Focus

We will grow by focusing on new patient groups and high-impact markets

Image descriptionSecond image description

The first pillar of our corporate strategy is ‘Focus’. It describes how ALK will prioritise and focus our commercial activities as we work to strengthen our global position in respiratory allergy, primarily through extending the reach of our current tablet portfolio.

We will focus on helping new patient groups, including children living with allergy. Key initiatives include:

  • Targeted expansion to new patient groups 
  • Investments in high-impact markets 
  • Efforts to increase prescription depth and breadth among healthcare professionals 
  • Digital mobilisation of eligible patients and prescribers

A significant growth contribution is expected to come from completing ALK’s respiratory tablet portfolio and by leveraging the expected full paediatric coverage. Across markets, ALK will also explore collaborations with partners to speed up commercial adoption.

Innovate

We will innovate to create a balanced pipeline

Image descriptionSecond image description

The second pillar of our corporate strategy is ‘Innovate’. To help more people with allergy, we will innovate and expand our R&D pipeline in a balanced way, maximising the value of our existing core products while diversifying our portfolio into food allergy, anaphylaxis and other adjacent, allergic diseases. Key initiatives include:

  • Strengthening the evidence supporting our core products in new patient groups, such as children and geographies 
  • Building a portfolio of treatment in food allergy that addresses the unmet medical need among the ~200 million people worldwide affected, particularly among children 
  • Continuing our prioritisation of treatment of acute life-threatening allergic reactions (anaphylaxis). The area is underserved - for instance, in the USA, where around 20 million people are at risk of suffering anaphylactic shocks, but only around 3 million carry an adrenaline autoinjector 
  • Proceeding innovation efforts targeting selected adjacent disease areas with strong scientific and commercial links to the existing product portfolio and channels, building on our scientific leadership and core R&D capabilities within molecular and clinical allergology and immunology

Overall, our focus will be on expanding our leadership into core areas, while exploring new solution areas that will drive our growth.

 

Optimise

We will optimise to create the right foundation for scaling

Image descriptionSecond image description

The third pillar of our corporate strategy is ‘Optimise’. To reduce complexity and maintain competitiveness, ALK will further optimise our operations and thereby create a robust foundation for future growth. We will simplify in order to scale and improve efficiency, while ensuring quality. Key initiatives include:

  • Continuous improvements of our manufacturing model while maintaining high quality excellence
  • Expansion of our production capacity for tablets 
  • Optimising the cost base, reducing structural complexities across the value chain, and investing in infrastructure such as digital solutions and AI

On the longer term, ALK will also explore options to optimise the global manufacturing footprint and further prune the product portfolio.

Cultivate

We will cultivate our unique capabilities to stay ahead and to grow sustainably

Image descriptionSecond image description

The fourth and final pillar of our corporate strategy is ‘Cultivate’. The activities and targets in this strategy are underpinned by ALK’s commitment to cultivate the capabilities of our people and organisation to foster a strong performance culture through high engagement, and to conduct business sustainably by improving access to allergy care and reducing the environmental footprint. Key initiatives include:

  • Investing in further development and upskilling of our employees to ensure that our organisation retains the right capabilities and an agile culture of continuous learning and growth 
  • Conducting business ethically and responsibly while fostering a safe, diverse and inclusive work environment 
  • Improving access to allergy care by expanding our reach among people with allergies through training of healthcare professionals and allergy awareness initiatives

We will also continue our focus to reach our science-based CO2 targets in line with the Paris Agreement. This includes reducing CO2 emissions from our own operations (scope 1 and 2) by 42% in 2030 and ensuring that 80% of emissions from our suppliers will come from suppliers that have science-based targets in place by 2028. Read more about our sustainability goals here.

 

Financial ambitions

We will continuously measure our progress

Image description

The Allergy+ strategy includes measurable financial ambitions, which will allow us to track our progress.

Our corporate strategy targets:

  • Average revenue growth of minimum 10% in local currencies (5-year CAGR) until 2028.
  • An EBIT margin of ~25% in 2025 after which we will aim for annual profitability improvements in line with revenue growth implying a projected EBIT margin of around 25% until 2028.

Reaching these financial targets, will enable our company to invest in strategic growth initiatives to bolster our long-term growth and profitability trajectory. We aspire to self-fund our development, implying that underlying margin improvements above ~25% will be reinvested in commercial activities, R&D, business development or infrastructure. This does not rule out that margins can be higher or lower in the strategy period subject to market conditions and the timing of strategic initiatives.

ALK will maintain an efficient capital structure with a financial gearing of maximum 2 x NIBD/EBITDA. Our organisation will be disciplined about capital allocation to ensure flexibility to deliver on our growth ambitions while also generating attractive shareholder returns.

Last updated: 02.06.2025

Cookie notice

Last updated: 08.01.2024

Legal disclaimer

This legal disclaimer shall apply to any and all access to the site and to all use of the site and its content.

Welcome to the ALK website. The aim of the ALK website is to give you an introduction to ALK. As such the website and its content is available solely for informational purposes. This legal disclaimer, as amended from time to time, shall apply to your access to and use of the website and its content.

By entering this website, you acknowledge and agree to this legal disclaimer.

Last updated: 07.01.2024

Legal disclaimer - ALK

Last updated: 16.11.2023

NPAD

Last updated: 12.01.2024

House dust mite allergy might be stealing your sleep

Last updated: 12.01.2024

Feeling ill all year around

Last updated: 12.01.2024

The monsters are closer than you think

Last updated: 13.11.2023